Aclaris announces ATI-450 (MK2 pathway Inhibitor) publication in Cancer Research
Aclaris announced publication in the journal Cancer Research: "Inhibition of the stromal p38MAPK/MK2 pathway limits breast cancer metastases and chemotherapy-induced bone loss." ATI-450 is a selective inhibitor of p38 mitogen-activated protein kinase-activated protein kinase 2. August 21, 2018